NOTICE: This document contains comments from the reviewers and editors generated during peer review of the initial manuscript submission and sent to the author via email.

Questions about these materials may be directed to the Obstetrics & Gynecology editorial office: obgyn@greenjournal.org.
RE: Manuscript Number ONG-19-2024

Efficacy, safety, and tolerability of a new low-dose copper and nitinol intrauterine device: Phase 2 data to 36-months

Dear Dr. Turok:

Your manuscript has been reviewed by the Editorial Board and by special expert referees. Although it is judged not acceptable for publication in Obstetrics & Gynecology in its present form, we would be willing to give further consideration to a revised version.

If you wish to consider revising your manuscript, you will first need to study carefully the enclosed reports submitted by the referees and editors. Each point raised requires a response, by either revising your manuscript or making a clear and convincing argument as to why no revision is needed. To facilitate our review, we prefer that the cover letter include the comments made by the reviewers and the editor followed by your response. The revised manuscript should indicate the position of all changes made. We suggest that you use the "track changes" feature in your word processing software to do so (rather than strikethrough or underline formatting).

Your paper will be maintained in active status for 21 days from the date of this letter. If we have not heard from you by Dec 27, 2019, we will assume you wish to withdraw the manuscript from further consideration.

REVIEWER COMMENTS:

Reviewer #1: Authors

Abstract

1. What is US MEC?

Intro

2. How does this IUD compare to IUDs on the market worldwide? CU SAFE 300 IUD? What would be its advantages over what's already available (i.e. why does another new copper IUD need to be created vs. bringing what's already on the market to US)?

3. Is phase 1 study published? I was only able to locate an abstract below in Contraception in 2014 but no paper.


4. For those not familiar with nitinol, why is it used in contraceptive devices?

5. Lines 93-99

How do dimensions and inserted compare to T380A, and to current IUDS on the market in US (Skyla, Kyleena, etc)? What size matter in terms of ease of insertion for smaller uterus/nulliparous uterus?

6. Would precut string length be a problem in large cavity? Immediate post-placental insertion, or large fibroid uterus? In those cases, leaving strings long and cutting them short later at another visit is an advantage

Methods

7. Pearl index vs. life tables.

Separating women into younger/older (ie more and less likely to get pregnant) is of help. Life table more useful than Pearl index, but good to have info about both.

8. Is it possible to know how many women took or were told to take NSAIDS for bleeding/cramping? It is common practice to do that with copper T, so is that something that occurred in this study?
9. Were subjects paid to participate?

10. Was the sample size set by FDA phase 2 requirements or some other considerations? My understanding FDA sets those numbers, but please explain for general audience

Results

11. Bleeding days decreased over time. Is that comparable with trends of other non-hormonal IUDs?

12. How does efficacy, ease of placement, and discontinuation rates data compare to other IUDs?

13. In table 3, dysmenorrhea and pain AI are high. Is there any more detail avail on that, along with post-procedural hemorrhage?

14. Fig 1 Looking at IUD picture, is there risk of arms/copper sleeves getting stuck in myometrium in case of partial perf resulting in embedded IUD? Those are hard to get out as arms break off and get stuck in existing iuds, but his seems like it would be even more problematic.

Discussion

15. Has this IUD been studies elsewhere aside from ref 2?

Reviewer #2: Overview: This manuscript describes 36-month data of a novel low-dose copper-nitinol IUD. Authors found high efficacy and tolerability, however a lack of included detail limits understanding of generalizability. I recommend the following revisions to improve the clarity and quality of the manuscript:

1. Title and Abstract: The title and abstract appropriately reflect the manuscript. Because the primary outcome was the 12-month Pearl Index, this should also be included in the abstract.

2. Introduction: The introduction clearly describes the reasoning for this study. Can delete sentence in lines 99-100 as it is redundant. Sentence in line 103-104 is incomplete (possibly: the copper-nitinol IUD was associated with lower pain scores).

3. Methods:
Role of Funding Source: more detail is required here, such as in this recent Green Journal article "Concordance of Fingerstick and Venipuncture Sampling for Fertility Hormones" February 2019. Alternately, a more concise version such as in "Patterns of Prescription Opioid Use in Women With Endometriosis: Evaluating Prolonged Use, Daily Dose, and Concomitant Use With Benzodiazepines" June 2019. Detail should be included in this section rather than throughout the manuscript.

Line 125-126: Did all participants agree to participate in the 2-year extension?

Line 132: change "last 3 months" to "3 months prior to enrollment"

Line 147: cite ASCCP guidelines

Line 150: include actual citation here

Line 151-152: what is "prescribed placement" of IUD?

Line 154: If IUD placement was not fundal, what was done?

4. Results: Why were the 131 screened participants not eligible? Please include either in text or Figure 2.

Line 218: were all 286 enrolled participants tested at time of insertion?

Paragraph lines 223-230 discusses low rate of discontinuation due to pain/bleeding, however only 37.8% of participants continued use to 36 months. Please include whether this discrepancy is due to LTFU or discontinuation for other reasons. Also include rate of discontinuation due to desire for pregnancy. Bleeding days are included in abstract but not in results.

Line 222: What percentage of cycles were the "assumed evaluable" rather than assessed directly?

Line 232: it seems as if the ectopic pregnancy is likely related to the study device as this is a known risk of FDA-approved IUDs. Were age or parity associated with discontinuation?

Figure 1: please also include a diagram of the inserter.

Figure 2: remove text that states "PLACEHOLDER"

5. Discussion: Inappropriate comparison to LNG IUD data. Consider citation for T380 comparison or including data for other smaller copper IUD such as Mona Lisa.

6. References: Include copper IUD comparator as noted in Discussion comment.
Reviewer #3: Easy to understand summary of Phase 2 trial for novel copper IUD. Exciting to see another non-hormonal contraceptive method moving closer to approval

A few questions:

What's the intended duration of use for this new IUD? I understand this study was for three years but is the intention to continue to collect data beyond that time? Were the patients all instructed to have the IUD removed at the end of 3 years?

It might be helpful to tell readers what nitinol is made of.

Lastly, African Americans are over-represented in the study (as compared to the percentage in the general population) and I'm wondering if you might comment on why that is. I think this is an especially important consideration in light of LARC coercion in previous contraceptive studies.

STATISTICAL EDITOR’S COMMENTS:

1. Abstract: Should include median (range) time for continuation and rate (or hazard rate) for discontinuation.

2. Table 1: For the column of 36-40 yo, the N = 25, so all percentages should be rounded to nearest integer, rather than citing to 0.1% precision.

3. Table 3: Should include CIs for the AE proportions.

4. Fig 3: The labels for K-M curves appear to have been reversed, with the subjects with device expulsion have essentially 100% continuation rates. Should include the "N" remaining in each cohort at the time increments along the x-axis.

EDITORIAL OFFICE COMMENTS:

1. The Editors of Obstetrics & Gynecology are seeking to increase transparency around its peer-review process, in line with efforts to do so in international biomedical peer review publishing. If your article is accepted, we will be posting this revision letter as supplemental digital content to the published article online. Additionally, unless you choose to opt out, we will also be including your point-by-point response to the revision letter. If you opt out of including your response, only the revision letter will be posted. Please reply to this letter with one of two responses:
   A. OPT-IN: Yes, please publish my point-by-point response letter.
   B. OPT-OUT: No, please do not publish my point-by-point response letter.

2. As of December 17, 2018, Obstetrics & Gynecology has implemented an "electronic Copyright Transfer Agreement" (eCTA) and will no longer be collecting author agreement forms. When you are ready to revise your manuscript, you will be prompted in Editorial Manager (EM) to click on "Revise Submission." Doing so will launch the resubmission process, and you will be walked through the various questions that comprise the eCTA. Each of your coauthors will receive an email from the system requesting that they review and electronically sign the eCTA.

Please check with your coauthors to confirm that the disclosures listed in their eCTA forms are correctly disclosed on the manuscript's title page.

3. Obstetrics & Gynecology follows the Good Publication Practice (GPP3)* guideline for manuscripts that report results that are supported or sponsored by pharmaceutical, medical device, diagnostics and biotechnology companies. The GPP3 is designed to help individuals and organization maintain ethical and transparent publication practices.

(1) Adherence to the GPP3 guideline should be noted in the cover letter.

(2) For publication purposes, the portions of particular importance to industry-sponsored research are below. In your cover letter, please indicate whether the following statements are true or false, and provide an explanation if necessary:
   (2a) All authors had access to relevant aggregated study data and other information (for example, the study protocol) required to understand and report research findings.
   (2b) All authors take responsibility for the way in which research findings are presented and published, were fully involved at all stages of publication and presentation development and are willing to take public responsibility for all aspects of the work.
(2c) The author list accurately reflects all substantial intellectual contributions to the research, data analyses, and publication or presentation development. Relevant contributions from persons who did not qualify as authors are disclosed in the acknowledgments.

(2d) The role of the sponsor in the design, execution, analysis, reporting, and funding (if applicable) of the research has been fully disclosed in all publications and presentations of the findings. Any involvement by persons or organizations with an interest (financial or nonfinancial) in the findings has also been disclosed.

(2e) All authors have disclosed any relationships or potential competing interests relating to the research and its publication or presentation.

(3) The abstract should contain an additional heading, "Funding Source," and should provide an abbreviated listing of the funder(s).

(4) In the manuscript, a new heading—"Role of the Funding Source"—should be inserted before the Methods and contain a detailed description of the sponsor's role as well as the following language:

"The authors had access to relevant aggregated study data and other information (such as study protocol, analytic plan and report, validated data table, and clinical study report) required to understand and report research findings. The authors take responsibility for the presentation and publication of the research findings, have been fully involved at all stages of publication and presentation development, and are willing to take public responsibility for all aspects of the work. All individuals included as authors and contributors who made substantial intellectual contributions to the research, data analysis, and publication or presentation development are listed appropriately. The role of the sponsor in the design, execution, analysis, reporting, and funding is fully disclosed. The authors' personal interests, financial or non-financial, relating to this research and its publication have been disclosed." Authors should only include the above statement if all of it is true, and they should attest to this in the cover letter (see #2, above).


4. Tables, figures, and supplemental digital content should be original. The use of borrowed material (e.g., lengthy direct quotations, tables, figures, or videos) is discouraged, but should it be considered essential, written permission of the copyright holder must be obtained. Permission is also required for material that has been adapted or modified from another source.

Both print and electronic (online) rights must be obtained from the holder of the copyright (often the publisher, not the author), and credit to the original source must be included in your manuscript. Many publishers now have online systems for submitting permissions requests; please consult the publisher directly for more information.

When you submit your revised manuscript, please upload 1) the permissions license and 2) a copy of the original source from which the material was reprinted, adapted, or modified (e.g., scan of book page(s), PDF of journal article, etc.).

5. Standard obstetric and gynecology data definitions have been developed through the reVITALize initiative, which was convened by the American College of Obstetricians and Gynecologists and the members of the Women's Health Registry Alliance. Obstetrics & Gynecology has adopted the use of the reVITALize definitions. Please access the obstetric and gynecology data definitions at https://www.acog.org/About-ACOG/ACOG-Departments/Patient-Safety-and-Quality-Improvement/reVITALize. If use of the reVITALize definitions is problematic, please discuss this in your point-by-point response to this letter.

6. Because of space limitations, it is important that your revised manuscript adhere to the following length restrictions by manuscript type: Original Research reports should not exceed 22 typed, double-spaced pages (5,500 words). Stated page limits include all numbered pages in a manuscript (i.e., title page, précis, abstract, text, references, tables, boxes, figure legends, and print appendixes) but exclude references.

7. Titles in Obstetrics & Gynecology are limited to 100 characters (including spaces). Do not structure the title as a declarative statement or a question. Introductory phrases such as "A study of..." or "Comprehensive investigations into..." or "A discussion of..." should be avoided in titles. Abbreviations, jargon, trade names, formulas, and obsolete terminology also should not be used in the title. Titles should include "A Randomized Controlled Trial," "A Meta-Analysis," or "A Systematic Review," as appropriate, in a subtitle. Otherwise, do not specify the type of manuscript in the title.

8. Specific rules govern the use of acknowledgments in the journal. Please note the following guidelines:

* All financial support of the study must be acknowledged.
* Any and all manuscript preparation assistance, including but not limited to topic development, data collection, analysis, writing, or editorial assistance, must be disclosed in the acknowledgments. Such acknowledgments must identify the entities that provided and paid for this assistance, whether directly or indirectly.
* All persons who contributed to the work reported in the manuscript, but not sufficiently to be authors, must be acknowledged. Written permission must be obtained from all individuals named in the acknowledgments, as readers may infer their endorsement of the data and conclusions. Please note that your response in the journal's electronic author form verifies that permission has been obtained from all named persons.
* If all or part of the paper was presented at the Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists or at any other organizational meeting, that presentation should be noted (include the exact dates and location of the meeting).

9. The most common deficiency in revised manuscripts involves the abstract. Be sure there are no inconsistencies between the Abstract and the manuscript, and that the Abstract has a clear conclusion statement based on the results found in the paper. Make sure that the abstract does not contain information that does not appear in the body text. If you submit a revision, please check the abstract carefully.

In addition, the abstract length should follow journal guidelines. The word limits for different article types are as follows: Original Research articles, 300 words. Please provide a word count.

10. Only standard abbreviations and acronyms are allowed. A selected list is available online at http://edmgr.ovid.com/ong/accounts/abbreviations.pdf. Abbreviations and acronyms cannot be used in the title or précis. Abbreviations and acronyms must be spelled out the first time they are used in the abstract and again in the body of the manuscript.

11. The journal does not use the virgule symbol (/) in sentences with words. Please rephrase your text to avoid using "and/or," or similar constructions throughout the text. You may retain this symbol if you are using it to express data or a measurement.

12. In your Abstract, manuscript Results sections, and tables, the preferred citation should be in terms of an effect size, such as odds ratio or relative risk or the mean difference of a variable between two groups, expressed with appropriate confidence intervals. When such syntax is used, the P value has only secondary importance and often can be omitted or noted as footnotes in a Table format. Putting the results in the form of an effect size makes the result of the statistical test more clinically relevant and gives better context than citing P values alone.

If appropriate, please include number needed to treat for benefits (NNTb) or harm (NNTh). When comparing two procedures, please express the outcome of the comparison in U.S. dollar amounts.

Please standardize the presentation of your data throughout the manuscript submission. For P values, do not exceed three decimal places (for example, "P = .001"). For percentages, do not exceed one decimal place (for example, 11.1%).

13. Please review the journal’s Table Checklist to make sure that your tables conform to journal style. The Table Checklist is available online here: http://edmgr.ovid.com/ong/accounts/table_checklist.pdf.

14. The Journal's Production Editor had the following comments about the figures in your manuscript:

"Figure 1: Please upload a high res version of this figure (eps, tiff, jpeg). Was this image created by an illustrator, or is it from another source? Figure 3: Please upload a high res version of this figure (eps, tiff, jpeg)."

When you submit your revision, art saved in a digital format should accompany it. If your figure was created in Microsoft Word, Microsoft Excel, or Microsoft PowerPoint formats, please submit your original source file. Image files should not be copied and pasted into Microsoft Word or Microsoft PowerPoint.

When you submit your revision, art saved in a digital format should accompany it. Please upload each figure as a separate file to Editorial Manager (do not embed the figure in your manuscript file).

If the figures were created using a statistical program (eg, STATA, SPSS, SAS), please submit PDF or EPS files generated directly from the statistical program.

Figures should be saved as high-resolution TIFF files. The minimum requirements for resolution are 300 dpi for color or black and white photographs, and 600 dpi for images containing a photograph with text labeling or thin lines.

Art that is low resolution, digitized, adapted from slides, or downloaded from the Internet may not reproduce.

15. Authors whose manuscripts have been accepted for publication have the option to pay an article processing charge and publish open access. With this choice, articles are made freely available online immediately upon publication. An information sheet is available at http://links.lww.com/LWW-ES/A48. The cost for publishing an article as open access can be found at http://edmgr.ovid.com/acd/accounts/ifauth.htm.

Please note that if your article is accepted, you will receive an email from the editorial office asking you to choose a publication route (traditional or open access). Please keep an eye out for that future email and be sure to respond to it promptly.

***

If you choose to revise your manuscript, please submit your revision through Editorial Manager at
http://ong.editorialmanager.com. Your manuscript should be uploaded in a word processing format such as Microsoft Word. Your revision's cover letter should include the following:

* A confirmation that you have read the Instructions for Authors (http://edmgr.ovid.com/ong/accounts/authors.pdf), and
* A point-by-point response to each of the received comments in this letter.

If you submit a revision, we will assume that it has been developed in consultation with your co-authors and that each author has given approval to the final form of the revision.

Again, your paper will be maintained in active status for 21 days from the date of this letter. If we have not heard from you by Dec 27, 2019, we will assume you wish to withdraw the manuscript from further consideration.

Sincerely,

The Editors of Obstetrics & Gynecology

2018 IMPACT FACTOR: 4.965
2018 IMPACT FACTOR RANKING: 7th out of 83 ob/gyn journals

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/ong/login.asp?a=r). Please contact the publication office if you have any questions.